Preventing low white blood cell counts in kids with solid tumors
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (like bone or muscle cancer) that needs strong chemotherapy.
- You have had at least 2 more rounds of chemo planned.
- In your last chemo round, you had a fever with low white blood cells (febrile neutropenia) or very low white blood cells that forced a change in your treatment.
- You are between 6 and 24 years old.
- You are generally well enough to do light activities (like walking or playing) without help.
- Your blood counts (red cells, white cells, platelets) are high enough to start a new chemo cycle.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This trial tests a new drug, Efbemalenograstim Alfa (a type of G-CSF), to prevent a drop in white blood cells (neutropenia) that can happen after chemotherapy combined with immunotherapy. It is for people with advanced lung or esophageal cancer who are at high risk for this complication.
This trial studies how safe eflapegrastim is in pediatric patients with certain solid tumors or lymphomas who are starting chemotherapy that lowers white blood cells. It also looks at how the medicine behaves in the body to help reduce the risk of dangerous infections.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
Hear when a new Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.